Circulating tumor DNA using a plasma-only assay predicts survival in patients with oligometastatic colorectal cancer after definitive therapy
Journal of Gastrointestinal Oncology · 2025-04 · 16 (2) · 580-590
DOI: 10.21037/jgo-24-819 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gastrointestinal Oncology, 2025-04. Verfasst von Enrique Sanz-Garcia und 19 weiteren Autor:innen. Beteiligte Einrichtung: HM CIOCC MADRID (Clara Campal Comprehensive Cancer Centre), Oncology Department, University Hospital HM Sanchinarro, HM Hospitales, Madrid, Spain. Die Arbeit wurde bisher 4-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Patients with colorectal cancer (CRC) and oligometastases are usually treated with surgery and radiation. The addition of adjuvant chemotherapy is controversial. The detection of circulating tumor DNA (ctDNA) may provide further insight in prognosis as well as help in decision of adjuvant therapies. We aim to show that detection of ctDNA after definitive therapy in oligometastatic CRC is associated with worse outcomes.
Methods
A single centre prospective study included patients with oligometastatic CRC treated with surgery or radiation with definitive intent. Plasma samples were collected before procedure and 4 weeks after, prior to adjuvant chemotherapy. Plasma samples were analyzed using a tumor-naive assay focusing on genomic and methylation alterations (Guardant Reveal). Disease-free survival (DFS) and overall survival (OS) were estimated using Kaplan Meier method.
Results
A total of 25 patients were included: 19 were evaluated at baseline and post-treatment. ctDNA detection at baseline was not associated with any clinicopathological characteristics, neither OS nor DFS. In contrast, patients with ctDNA detection post-treatment had worse OS [hazard ratio (HR): 11.28; 95% confidence interval (CI): 1.31-97.05] and a trend to shorter DFS (HR: 2.97; 95% CI: 0.97-9.06). Patients who were persistently negative or cleared ctDNA had similar outcomes. Conclusions: ctDNA detection after surgery/radiation in oligometastatic CRC predicts worse OS and DFS. ctDNA could help to guide the decision regarding need of adjuvant chemotherapy in this population.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- HM CIOCC MADRID (Clara Campal Comprehensive Cancer Centre), Oncology Department, University Hospital HM Sanchinarro, HM Hospitales, Madrid, Spain.
- Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada.
- HM Hospitales Health Research Institute, Madrid, Spain.
- Department of Medicine, HM Health Faculty, Camilo José Cela University, Boadilla del Monte, Spain.
- Respiratory Diseases Networking Biomedical REsearch Centre (CIBERES), Carlos III Health Institute (ISCIII), Madrid, Spain.
- Data Analysis Department, HM Hospitales Research Foundation, HM Hospitales, Madrid, Spain.
ORCID-Profile: Enrique Sanz-Garcia
Zitieren
APA
Sanz-Garcia, E., Peinado, P., Peláez, A., Lopez-Aranda, E. G., Álvarez-Gallego, R., Muñoz, C., Toledano, C., Mihic, L., Ortega, J., Lazaro, A., Montesino, B. M., Bressel, C., Gonzalo, A., Hernando, O., Lopez, M., Rubio, C., Fabra, I., Quijano, Y., Vicente, E., & Cubillo, A. (2025). Circulating tumor DNA using a plasma-only assay predicts survival in patients with oligometastatic colorectal cancer after definitive therapy. Journal of Gastrointestinal Oncology, 16(2), 580-590. https://doi.org/10.21037/jgo-24-819
Vancouver
Sanz-Garcia E, Peinado P, Peláez A, Lopez-Aranda EG, Álvarez-Gallego R, Muñoz C, et al. Circulating tumor DNA using a plasma-only assay predicts survival in patients with oligometastatic colorectal cancer after definitive therapy. Journal of Gastrointestinal Oncology. 2025;16(2):580-590. doi:10.21037/jgo-24-819
BibTeX
@article{SanzGarcia2025,
author = {Sanz-Garcia, Enrique and Peinado, Paloma and Peláez, Adrián and Lopez-Aranda, Elena Gonzalez and Álvarez-Gallego, Rafael and Muñoz, César and Toledano, Carmen and Mihic, Luka and Ortega, Justo and Lazaro, Almudena and Montesino, Begoña Martinez and Bressel, Cristina and Gonzalo, Alicia and Hernando, Ovidio and Lopez, Mercedes and Rubio, Carmen and Fabra, Isabel and Quijano, Yolanda and Vicente, Emilio and Cubillo, Antonio},
title = {Circulating tumor DNA using a plasma-only assay predicts survival in patients with oligometastatic colorectal cancer after definitive therapy},
journal = {Journal of Gastrointestinal Oncology},
year = {2025},
volume = {16},
number = {2},
pages = {580--590},
doi = {10.21037/jgo-24-819}
}
EUVIMED